In the six OHDA rat model of PD, both a daily high dose (12IU) for 2 weeks and a daily low dose (3IU) for 4 weeks of intranasal insulin alleviated motor deficits observed in the model in overall locomotor activity and in a variety of motor behavioral tests (Pang et al., 2016; Fine et al., 2020). The gene discussed is INS; the disease is Parkinson disease.